Fortune Feature Examines Controversy Over Sanofi Dengue Vaccine In Philippines

Fortune: Epidemic of Fear: How the Trouble-Ridden Debut of a Breakthrough Vaccine Sparked a Panic
“…[W]hile the Philippine news media and most of the politicians involved have moved on, the Dengvaxia controversy continues to have a profound and lasting impact. … In the Philippines, where immunization coverage was already dangerously low, the Dengvaxia scare caused vaccination rates to fall even further, opening the door to infectious diseases once believed to be on the wane. … Which brings up the first of this tale’s tragic, even Shakespearean twists: the fact that the Dengvaxia controversy may well bury forever a vaccine that actually works — not for everyone but for huge swaths of populations in countries where dengue is an urgent and growing public health problem. … Twist No. 2 is this: There is a good chance that Dengvaxia didn’t cause the tragic deaths of those 148 children…” (Fry, 11/26).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.